Interim accommodation offered by Amsterdam in its winning bid was “not acceptable” says EMA director, Guido Rasi. Now the agency faces a ‘double transfer’ out of London, increasing costs and delaying the return to normal operations
More than a year after the public consultation closed, EMA and the Commission have announced moves that aim to clear the regulatory logjam holding back commercialisation of therapies based on tissues, cells and genes
Employees are lukewarm on new locations and a slow-down in work rate will mean less income. In the best case scenario Europe’s drugs regulator will take 2-3 years to get back to speed after leaving London.
Only 5 of 19 cities bidding to host the European Medicines Agency would attract enough current employees for operations to continue as normal. Moving to one of the 8 least popular cities risks permanent damage, the agency warns